Dynamic quotes: Off
|
Company Description (as filed with the SEC)
Myriad Genetics, Inc. is a leading molecular diagnostic company focused on developing and marketing novel predictive medicine, personalized medicine and prognostic medicine products. We believe that the future of medicine lies in a shift from a treatment paradigm to a prevention paradigm. By understanding the genetic basis of disease, we believe that individuals who have a greater risk of developing disease can be identified and physicians can use this information to improve patient outcomes and better manage patient healthcare. We employ a number of proprietary technologies that help us to understand the genetic basis of human disease and the role that genes and their related proteins may play in the onset and progression of disease. ... More ...
Analyst Info |
|
| Annual EPS Est: | $1.3 |
| Quarterly EPS Est: | 0.43 |
| PEG Ratio: | 1.54 |
|
Mean Recommendation: View Summary / View All |
2.18 |
Data is provided by Zacks Investment Research

